Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
A phase 3 trial of Durvalumab, Tremelimumab, Cisplatin, Carboplatin and Gemcitabine in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer is a phase 3 interventional study registered as NCT02516241 by AstraZeneca, with 1126 participants enrolled, started 2015-11-02 and due to reach its primary completion in 2020-01-27. Interventions recorded: MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin and Gemcitabine. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Tremelimumab, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
- TrialPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Shares Tremelimumab, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
- TrialStudy of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Shares Tremelimumab, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
- TrialStudy of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, AstraZeneca, Carboplatin and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Tremelimumab, Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialTreatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Shares Tremelimumab, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Durvalumab, Gemcitabine, Cisplatin, AstraZeneca and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.